Stevanato Group S.p.A.
STVN
ISIN IT0005452658 / Valor 112611283
Stevanato Group S.p.A.
UMushroom community rating:
About company
Stevanato Group S.p.A., headquartered in Piombino Dese, Padua, Italy, is a global leader in the pharmaceutical packaging and drug delivery systems sector, with a focus on the production of high-quality glass and plastic components. The company's origins trace back to the establishment of Soffieria Stella near Venice, specializing in glass bottle production, before moving to Piombino Dese in 1959. Over the years, Stevanato Group has expanded its expertise and product offerings through strategic acquisitions and internal development. It acquired Balda, enhancing its capabilities in plastic development for diagnostic consumables, drug delivery systems, and medical components. The acquisition of Optrel furthered its competencies in the manufacture of inspection machines for glass containers in the pharmaceutical industry. Stevanato Group has also established a presence in the United States with its Technology Excellence Center in Boston, Massachusetts, aimed at providing integrated analytical services for drug development and commercialization. The company's international footprint was further expanded with the addition of Medical Glass in Slovakia. Stevanato Group's product portfolio includes high-speed, high-precision glass forming lines, EZ-fill® ready-to-fill sterilized syringes, vials, and cartridges, showcasing its commitment to supporting the pharmaceutical industry's needs for reliable and innovative packaging solutions.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (20.12.2024):
Revenue Growth
In the third quarter of 2024, Stevanato Group S.p.A. reported a 2% increase in revenue, reaching €277.9 million compared to the same period last year. This growth was primarily driven by a 6% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which helped offset a 15% decline in the Engineering Segment.
Earnings Per Share
For the third quarter of 2024, Stevanato Group S.p.A. reported diluted earnings per share of €0.11 and adjusted diluted earnings per share of €0.12. The company has adjusted its full-year guidance for adjusted diluted EPS to a range of €0.47 to €0.49, reflecting higher costs.
Profit Margins
Stevanato Group S.p.A. experienced a decrease in gross profit margin to 26.8% in the third quarter of 2024, down from 30.5% in the same period last year. This decline was attributed to factors such as vial destocking, underutilization of vial lines, and higher costs related to the start-up of a new U.S. manufacturing facility.
Cash Flow and Capital Expenditures
As of September 30, 2024, Stevanato Group S.p.A. had cash and cash equivalents of €78.0 million and net debt of €284.3 million. The company reported negative free cash flow of €28.4 million for the third quarter, driven by capital expenditures totaling €58.8 million to support strategic initiatives.
Updated Financial Guidance
Stevanato Group S.p.A. is maintaining its full-year 2024 revenue guidance, expecting revenue in the range of €1,090 million to €1,110 million. However, the company has lowered its adjusted EBITDA guidance to a range of €257 million to €263 million, reflecting higher costs in the Engineering Segment and increased validation activities.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
8668 M
Market cap (USD)
47,363
Daily traded volume (Shares)
22.24 / 21.08
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
